Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.

The release of aspirin from a 75 mg controlled-release formulation, designed to inhibit maximally thromboxane A2 production while sparing stimulated prostacyclin biosynthesis, was characterised in healthy subjects. The calculated in vivo release rate of aspirin matched the design goal of approximate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Charman, W N, Charman, S A, Monkhouse, D C, Frisbee, S E, Lockhart, E A, Weisman, S, Fitzgerald, G A
Formato: Artigo
Idioma:Inglês
Publicado em: 1993
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1364623/
https://ncbi.nlm.nih.gov/pubmed/12959298
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados